187 related articles for article (PubMed ID: 37971319)
1. Tumor immune evasion: insights from CRISPR screens and future directions.
Djajawi TM; Wichmann J; Vervoort SJ; Kearney CJ
FEBS J; 2024 Apr; 291(7):1386-1399. PubMed ID: 37971319
[TBL] [Abstract][Full Text] [Related]
2. Tumor immunology CRISPR screening: present, past, and future.
Dong MB; Tang K; Zhou X; Zhou JJ; Chen S
Trends Cancer; 2022 Mar; 8(3):210-225. PubMed ID: 34920978
[TBL] [Abstract][Full Text] [Related]
3. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
Potts MA; McDonald JA; Sutherland KD; Herold MJ
Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
[TBL] [Abstract][Full Text] [Related]
4. High-content CRISPR screening in tumor immunology.
Holcomb EA; Pearson AN; Jungles KM; Tate A; James J; Jiang L; Huber AK; Green MD
Front Immunol; 2022; 13():1041451. PubMed ID: 36479127
[TBL] [Abstract][Full Text] [Related]
5. Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens.
Yim S; Hwang W; Han N; Lee D
Front Immunol; 2022; 13():884561. PubMed ID: 35651625
[TBL] [Abstract][Full Text] [Related]
6. Advancements in CRISPR screens for the development of cancer immunotherapy strategies.
Li YR; Lyu Z; Tian Y; Fang Y; Zhu Y; Chen Y; Yang L
Mol Ther Oncolytics; 2023 Dec; 31():100733. PubMed ID: 37876793
[TBL] [Abstract][Full Text] [Related]
7. CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets.
Noorani I; Bradley A; de la Rosa J
Genome Biol; 2020 Aug; 21(1):204. PubMed ID: 32811551
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Based Approaches for Cancer Immunotherapy.
Malla RR; Middela K
Crit Rev Oncog; 2023; 28(4):1-14. PubMed ID: 38050977
[TBL] [Abstract][Full Text] [Related]
9. Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies.
Xiang M; Li H; Zhan Y; Ma D; Gao Q; Fang Y
Mol Cancer; 2024 Apr; 23(1):73. PubMed ID: 38581063
[TBL] [Abstract][Full Text] [Related]
10. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.
Dubrot J; Du PP; Lane-Reticker SK; Kessler EA; Muscato AJ; Mehta A; Freeman SS; Allen PM; Olander KE; Ockerman KM; Wolfe CH; Wiesmann F; Knudsen NH; Tsao HW; Iracheta-Vellve A; Schneider EM; Rivera-Rosario AN; Kohnle IC; Pope HW; Ayer A; Mishra G; Zimmer MD; Kim SY; Mahapatra A; Ebrahimi-Nik H; Frederick DT; Boland GM; Haining WN; Root DE; Doench JG; Hacohen N; Yates KB; Manguso RT
Nat Immunol; 2022 Oct; 23(10):1495-1506. PubMed ID: 36151395
[TBL] [Abstract][Full Text] [Related]
11. Improving Cancer Immunotherapy with CRISPR-Based Technology.
Li Z; Fei T
Adv Biosyst; 2020 Nov; 4(11):e1900253. PubMed ID: 33245213
[TBL] [Abstract][Full Text] [Related]
12. Interrogating immune cells and cancer with CRISPR-Cas9.
Buquicchio FA; Satpathy AT
Trends Immunol; 2021 May; 42(5):432-446. PubMed ID: 33812776
[TBL] [Abstract][Full Text] [Related]
13. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
[TBL] [Abstract][Full Text] [Related]
14. Cancer Immunotherapy: Diverse Approaches and Obstacles.
Sanatkar SA; Heidari A; Rezaei N
Curr Pharm Des; 2022; 28(29):2387-2403. PubMed ID: 35909273
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy.
Chen C; Wang Z; Qin Y
Exp Hematol Oncol; 2023 Nov; 12(1):95. PubMed ID: 37964355
[TBL] [Abstract][Full Text] [Related]
16. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators.
Hou J; Wang Y; Shi L; Chen Y; Xu C; Saeedi A; Pan K; Bohat R; Egan NA; McKenzie JA; Mbofung RM; Williams LJ; Yang Z; Sun M; Liang X; Rodon Ahnert J; Varadarajan N; Yee C; Chen Y; Hwu P; Peng W
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589527
[TBL] [Abstract][Full Text] [Related]
17. Engineered CRISPR Systems for Next Generation Gene Therapies.
Pineda M; Moghadam F; Ebrahimkhani MR; Kiani S
ACS Synth Biol; 2017 Sep; 6(9):1614-1626. PubMed ID: 28558198
[TBL] [Abstract][Full Text] [Related]
18. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target.
Wang X; Tokheim C; Gu SS; Wang B; Tang Q; Li Y; Traugh N; Zeng Z; Zhang Y; Li Z; Zhang B; Fu J; Xiao T; Li W; Meyer CA; Chu J; Jiang P; Cejas P; Lim K; Long H; Brown M; Liu XS
Cell; 2021 Oct; 184(21):5357-5374.e22. PubMed ID: 34582788
[TBL] [Abstract][Full Text] [Related]
19. Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion.
Freeman AJ; Vervoort SJ; Ramsbottom KM; Kelly MJ; Michie J; Pijpers L; Johnstone RW; Kearney CJ; Oliaro J
Cell Rep; 2019 Sep; 28(11):2784-2794.e5. PubMed ID: 31509742
[TBL] [Abstract][Full Text] [Related]
20. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
